Crinetics stock jumps 99% after Vertex Pharmaceuticals says it’s buying the endocrine treatment specialist for $10 billion.
Roivant Sciences (NASDAQ: ROIV) certainly seems like a rising star. The biotech stock has more than tripled over the past ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results